Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).
Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).
Bhishamjit S. Chera, MD, of the University of North Carolina, discusses quantification of human papillomavirus 16 in circulating tumor DNA during de-intensified chemoradiation therapy for favorable-risk HPV-associated oropharyngeal squamous cell carcinoma (Presentation 92).
Tamim Niazi, MDCM, of McGill University, discusses phase III study findings on hypofractionated, dose-escalation radiation therapy for high-risk adenocarcinoma of the prostate (Abstract 281).
James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).
Shulian Wang, MD, of the National Cancer Center in Beijing, and Benjamin Movsas, MD, of the Henry Ford Health System, discuss study results on the use of hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer (Abstract PL01).
